George MM*, Brennick CA*, Hagymasi AT, Shcheglova T, Al Seesi S , Rosales TJ, Baker BM, Mandoiu I , Srivastava PK. “A frameshift generated mouse cancer neoepitope which controls tumor burden in prophylaxis as well as therapy.” The Journal of Immunology, 2025. https://doi.org/10.1093/jimmun/vkaf016. *Co-first authors

Brennick CA, George MM, Gillig MA. “Neoepitope-Based Cancer Vaccines: Principles and Applications.” In: Das Mohapatra, A., Sahu, P.S. (eds) Advances in Immunology and Immuno-techniques. Interdisciplinary Biotechnological Advances. Springer, Singapore. 2024. https://doi.org/10.1007/978-981-97-5508-0_3

Liu, S.; Ji, F.; Ding, Y.; Ding, B.; Feng, S.; Brennick, CA.; Lin, H.; Zhang, T.; Shen, Y. VISTA: A Promising Target for Overcoming Immune Evasion in Gynecologic Cancers.International Immunopharmacology 2024, 138, 112655.

Srivastava PK, Mandoiu II, Brennick CA, George MM, and Moussa MM. “Unbiased identification of tumor rejection mediating neoepitopes.” US patent US11920202B2. 2024.

Gillig MA*, Brennick CA*, George MM*,. Balsbaugh JL, Shcheglova TV, Baker BM, Srivastava PK, Karandikar SH. “CD8+ T Cell–Dependent Antitumor Activity In Vivo of a Mass Spectrometry–Identified Neoepitope despite Undetectable CD8+ Immunogenicity In Vitro”. J Immunol 15 December 2023; 211 (12): 1783–1791. *Co-first authors

Brennick CA*, George MM*, Moussa, MM, Hagymasi AT, Seesi SA, Shcheglova TV, Englander RP, Keller GLJ, Balsbaugh JL, Baker BM, Schietinger A, Mandoiu II, Srivastava PK. An unbiased approach to defining bona fide cancer neoepitopes that elicit immune-mediated cancer rejection.” J Clin Invest 131. 2021. *Co-first authors

Brennick CA, George MM, Srivastava PK, Karandikar SH. “Prediction of cancer neoepitopes needs new rules.” Semin Immunol. 2020.

Brennick CA, George MM, Corwin WL, Srivastava PK, Ebrahimi-Nik H. “Neoepitopes as Cancer Immunotherapy Targets: Key Challenges and Opportunities.” Immunotherapy, vol. 9, no. 4, 2017, pp. 361–371.